India Biosimilars Market Size & Share 2026-2035

India Biosimilars Market Size

The India biosimilars market was valued at USD 1.5 billion in 2025. The market is estimated to grow from USD 1.9 billion in 2026 to USD 8.1 billion in 2035, growing at a CAGR of 17.8% over the analysis period, according to the latest report published by Global Market Insights Inc.

The market is experiencing strong growth, primarily stimulated by the rising burden of chronic diseases, increasing demand for affordable biologic treatments, and expanding government support for biopharmaceutical development. India has one of the largest patient populations requiring biologic therapies, particularly for diabetes, cancer, and autoimmune disorders. According to the International Diabetes Federation Diabetes Atlas 2025, approximately 89.8 million adults in India (10.5% prevalence) were living with diabetes in 2024, highlighting a significant and growing demand for long-term biologic and biosimilar therapies.

Additionally, the high cost of biologics continues to limit access to treatment, with healthcare expenditures pushing an estimated 32–39 million Indians into poverty annually, reinforcing the need for cost-effective alternatives such as biosimilars. Government initiatives are further supporting market growth; for instance, the Biopharma SHAKTI program with about USD 1 billion investment aims to strengthen domestic manufacturing and innovation in biologics and biosimilars, while public healthcare programs like Ayushman Bharat are improving treatment accessibility.

Biosimilars are highly similar versions of approved biologic medicines that demonstrate comparable safety, efficacy, and quality profiles to reference biologics while offering significantly lower treatment costs. These therapies have emerged as critical alternatives for managing chronic and life-threatening diseases requiring complex biologic interventions, thereby expanding patient access and helping reduce treatment disparities across healthcare systems. Biosimilars undergo extensive analytical, clinical, and regulatory evaluations to establish biosimilarity and therapeutic equivalence with originator biologics.

Key players operating in the India biosimilars market include Biocon Biologics, Dr. Reddy’s Laboratories, Zydus Lifesciences, Intas Pharmaceuticals, and Reliance Life Sciences, along with multinational companies through partnerships and commercialization activities. India has established itself as a global biosimilars hub, with over 135 biosimilars approved as of early 2025, reflecting one of the largest biosimilar portfolios worldwide. The presence of more than 30 companies actively engaged in biosimilar development, combined with strong manufacturing capabilities and export-driven strategies, is further strengthening the competitive landscape in India.

Between 2022 and 2024, the India biosimilars market increased from USD 839.7 million in 2022 to USD 1.3 billion in 2024, growing at a steady historical CAGR of 22.6%, supported by increasing domestic demand, new product launches, and rising global export opportunities. India’s broader biopharmaceutical sector expanded significantly during this period, with biologics and biosimilars gaining prominence as key growth drivers.

Additionally, the country’s strong manufacturing base, cost-efficient production capabilities, and rising demand for affordable biologics contributed to increased adoption. Government-backed healthcare access programs and improvements in regulatory frameworks further enhanced the uptake of biosimilars across therapeutic areas such as oncology, diabetes, and immunology.

India Biosimilars Market Trends

The India biosimilars industry is witnessing robust growth as healthcare providers, patients, and government stakeholders increasingly focus on improving access to affordable biologic therapies. Rising healthcare expenditure, expanding treatment coverage, and growing awareness of biologic medicines are encouraging the adoption of biosimilars across hospitals, specialty clinics, and tertiary care centers. India's strong biopharmaceutical manufacturing base and cost-efficient production ecosystem further support market expansion.

• India has emerged as one of the leading biosimilar development hubs globally, supported by a favorable regulatory environment and a large base of domestic manufacturers. The country has approved more than 135 biosimilars across multiple therapeutic categories, reflecting its strong capabilities in biologics research, development, and commercialization. The increasing availability of biosimilar alternatives is creating opportunities for broader patient access while intensifying competition within high-value biologic segments.
• Further, the growing burden of chronic diseases such as cancer, diabetes, autoimmune disorders, and chronic kidney diseases continues to drive demand for biologic therapies and related biosimilars. With a large patient population requiring long-term treatment, healthcare providers are increasingly adopting biosimilars to improve affordability and treatment accessibility while maintaining clinical effectiveness.
• Additionally, increasing physician confidence and patient acceptance are contributing to higher biosimilar utilization across India. Expanding clinical evidence, greater familiarity with biosimilar products, and the successful commercialization of multiple biosimilars have strengthened trust in their safety, efficacy, and quality, supporting their integration into routine clinical practice.
• So, regulatory advancements are further supporting market growth. India's biosimilar regulatory framework has evolved significantly, providing clearer approval pathways and encouraging domestic innovation. Continued efforts to align development standards with global scientific and regulatory practices are helping manufacturers accelerate product development while maintaining high quality and compliance standards.
• Investments in biologics manufacturing infrastructure, advanced bioprocessing technologies, and capacity expansion initiatives are enhancing production efficiency and supply reliability. Leading Indian biosimilar manufacturers are actively expanding their manufacturing capabilities and strengthening research and development programs to support both domestic demand and export opportunities in regulated international markets.

India Biosimilars Market Analysis

Based on the product, the India biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and other products. The recombinant glycosylated proteins segment has asserted its dominance in the market by securing a significant market share of 69.4% in 2025 owing to the widespread use of glycosylated biologics such as monoclonal antibodies, erythropoietin, and fusion proteins in the treatment of high-burden diseases. The segment is expected to exceed USD 5.6 billion by 2035, growing at a CAGR of 17.8% during the forecast period.

• Recombinant glycosylated proteins, including monoclonal antibodies, erythropoietin, and fusion protein therapies, are extensively used in the treatment of cancer, chronic kidney disease, autoimmune disorders, and hematological conditions, driving strong demand across India's healthcare system. Their growing importance in managing complex and chronic diseases has increased adoption across hospitals, specialty clinics, and tertiary care centers.
• Further, the dominance of the segment is further supported by the availability of multiple approved biosimilars for high-value biologics, rising physician confidence in biosimilars therapies, and the expanding presence of domestic manufacturers.
• Additionally, increasing investments in biologics manufacturing, favorable regulatory support for biosimilar development, and growing efforts to improve access to advanced therapies are accelerating the uptake of recombinant glycosylated protein biosimilars across the country.
• The recombinant non-glycosylated proteins segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 18.1% over the forecast period. The segment is driven by the widespread use of insulin, human growth hormone, granulocyte colony-stimulating factor (G-CSF), and interferon therapies in managing chronic conditions such as diabetes, hormonal disorders, neutropenia, and infectious diseases.

Based on application, the India biosimilars market is divided into hematology, oncology, autoimmune disease, ophthalmology, growth hormone deficiency, diabetes, and other applications. The hematology segment is further divided into neutropenia, anemia, and other hematology applications. The hematology segment dominated the market with a revenue share of 31.2% in 2025 and is expected to reach USD 2.5 billion within the forecast period.

• The hematology segment benefits from the extensive utilization of biosimilars such as erythropoietin and granulocyte colony-stimulating factor (G-CSF) in the management of anemia, neutropenia, and blood-related complications associated with chronic kidney disease and cancer treatment. The increasing requirement for supportive care therapies across large hospital networks continues to sustain demand for hematology biosimilars.
• Furthermore, established prescribing patterns, broader clinical familiarity, and the long-standing availability of hematology biosimilars in India have contributed to strong market penetration. The segment also benefits from routine use in nephrology and oncology treatment pathways, reinforcing its leadership within the biosimilars landscape.
• The oncology segment is anticipated to grow at a CAGR of 18.4% over the forecast period, propelled by increasing adoption of biosimilar monoclonal antibodies for the treatment of various solid tumors and hematological malignancies, alongside growing demand for cost-efficient targeted therapies.
• The autoimmune disease segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 18.1% over the forecast period. Growth is supported by the expanding use of biosimilars for rheumatoid arthritis, psoriasis, ankylosing spondylitis, and other immune-mediated disorders requiring long-term biologic treatment.
• The ophthalmology segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.1% over the forecast period. This segment is driven by increasing utilization of biologic therapies for retinal disorders and growing awareness regarding advanced treatment options for vision-threatening diseases.
• The growth hormone deficiency segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 16.7% over the forecast period. The segment is supported by rising diagnosis rates, greater treatment awareness, and increasing availability of recombinant growth hormone biosimilars.
• The diabetes segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.9% over the forecast period. The segment is driven by the widespread use of insulin biosimilars and a growing preference for affordable biologic therapies for long-term diabetes management.

Based on manufacturing type, the India biosimilars market is divided into contract research and manufacturing services, and in-house. The in-house segment dominated the market in 2025 with USD 1 billion.

• The leading position of the in-house segment is attributed to the presence of established Indian biopharmaceutical companies that possess integrated capabilities spanning research, development, manufacturing, and commercialization. Internal production enables greater oversight of product quality, process optimization, and compliance with stringent regulatory requirements.
• Additionally, companies continue to invest in dedicated biologics facilities and advanced manufacturing technologies to enhance operational efficiency and ensure uninterrupted production. These strategic investments have strengthened the preference for in-house manufacturing across the Indian biosimilars industry.
• The contract research and manufacturing services segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 18% over the forecast period. The segment is supported by increasing outsourcing activities, rising demand for specialized biologics expertise, and the need among emerging developers to access manufacturing infrastructure without substantial capital expenditure.

Based on technology, the India biosimilars market is divided into recombinant DNA technology, mammalian cell culture systems, and other technologies. The recombinant DNA technology segment dominated the market in 2025, growing at a CAGR of 17.8% during the forecast period.

• The prominence of recombinant DNA technology is linked to its extensive application in the production of established biosimilars, including insulin, growth hormones, interferons, and colony-stimulating factors. Its proven manufacturing framework and long history of commercial utilization have made it the preferred technology platform among biosimilar developers.
• Moreover, Indian manufacturers have accumulated significant expertise in recombinant biologics production, supported by established development infrastructure and scalable manufacturing processes. Technology continues to serve as a foundation for a broad range of biosimilar programs across multiple therapeutic areas.
• The mammalian cell culture systems segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 18.1% over the forecast period. The segment is gaining momentum due to the increasing development of sophisticated biologics, particularly monoclonal antibodies and fusion proteins, which require advanced cellular expression systems to replicate complex molecular structures.

Based on distribution channel, the India biosimilars market is divided into hospital pharmacies, specialty pharmacies, and other distribution channels. The hospital pharmacies segment dominated the market in 2025 with a market share of 53.2%.

• Hospital pharmacies remain the primary distribution avenue for biosimilars in India, as a substantial proportion of biologic therapies are prescribed, administered, and monitored within multispecialty hospitals and tertiary healthcare institutions. The requirement for specialist supervision and clinical monitoring further reinforces the central role of hospital settings.
• In addition, institutional procurement practices and bulk purchasing arrangements adopted by hospitals contribute to consistent biosimilar utilization. Access to trained healthcare professionals and infusion facilities also supports the concentration of biologic treatment delivery within hospital networks.
• The specialty pharmacies segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 18% over the forecast period. The segment is driven by increasing demand for specialized biologic dispensing services, patient adherence programs, cold-chain management capabilities, and personalized support for patients receiving long-term biologic therapies.

India Biosimilars Market Share

The top 5 companies in the India biosimilars industry, namely Biocon Biologics, Intas Pharmaceuticals, Dr. Reddy's Laboratories, Zydus Lifesciences, and Reliance Life Sciences, collectively accounted for approximately 49% of the market share in 2025. These companies have established strong positions through extensive biosimilar portfolios, well-developed biologics manufacturing capabilities, robust research and development infrastructure, and broad commercial presence across key therapeutic areas, including oncology, diabetes, immunology, nephrology, and hematology.

Indian biosimilar manufacturers are increasingly focusing on the development of high-value biologics, particularly monoclonal antibodies, insulin products, and other complex recombinant therapies, while expanding their footprint in both domestic and international markets. Strategic partnerships, product launches, capacity expansion initiatives, and investments in advanced bioprocessing technologies are enabling companies to enhance production efficiency, strengthen regulatory compliance, and accelerate market penetration. Furthermore, growing healthcare access, increasing physician confidence in biosimilars, and continued efforts to improve the affordability of biologic therapies are supporting wider adoption and intensifying competition across the India biosimilars industry.

India Biosimilars Market Companies

Major players operating in the India biosimilars industry are:

• Aurobindo Pharma
• Biocon Biologics
• Dr. Reddy's Laboratories
• Emcure Pharmaceuticals
• Hetero Biopharma
• Intas Pharmaceuticals
• Lupin Limited
• Reliance Life Sciences
• Sun Pharmaceutical Industries
• Torrent Pharmaceuticals
• Viatris India
• Wockhardt Limited
• Zydus Lifesciences
• Cadila Pharmaceuticals
• Stelis Biopharma

• Biocon Biologics

Biocon Biologics combines extensive biosimilar development expertise with large-scale biologics manufacturing capabilities, enabling strong commercialization across India and international markets. For example, Ogivri (trastuzumab biosimilar) and Semglee (insulin glargine biosimilar) have strengthened the company's presence in oncology and diabetes care, expanding access to affordable biologic therapies while maintaining established quality and efficacy standards.

• Intas Pharmaceuticals

Intas Pharmaceuticals leverages a diversified biosimilars portfolio, strong manufacturing infrastructure, and growing biologics expertise to expand its position in the biosimilars market. For example, Accofil (filgrastim biosimilar) has achieved broad adoption in supportive cancer care by helping manage chemotherapy-induced neutropenia while offering a cost-effective alternative to reference biologics and supporting wider patient access to treatment.

India Biosimilars Industry News

• In December 2025, Zydus Lifesciences launched Zyrifa, a biosimilar denosumab, in India for the prevention of skeletal-related complications in cancer patients. The launch expanded access to affordable biologic therapies and strengthened Zydus’ oncology biosimilars portfolio.
• In August 2025, Intas Pharmaceuticals, through its global Accord platform, completed the acquisition of UDENYCA (pegfilgrastim biosimilar), strengthening its position in oncology supportive care and expanding its global biosimilars footprint.
• In June 2025, Dr. Reddy’s Laboratories and Alvotech entered into a collaboration and licensing agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets. The partnership strengthens Dr. Reddy’s oncology biosimilars pipeline and enhances its capabilities in high-value immuno-oncology therapies.

The India biosimilars market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Recombinant non-glycosylated proteins 

  • Human growth hormone
  • Granulocyte colony-stimulating factor (filgrastim)
  • Insulin
  • Interferon
    • Alfa
    • Beta
• Recombinant glycosylated proteins 
  • Monoclonal antibodies 
    • Infliximab
    • Rituximab
    • Adalimumab
    • Trastuzumab
    • Bevacizumab
  • Erythropoietin
    • Alfa
    • Beta
  • Follitropin
    • Alfa
    • Beta
  • Fusion proteins
• Other products

Market, By Application

• Hematology

  • Neutropenia 
  • Anemia
  • Other hematology applications
• Oncology 
  • Lung cancer
  • Brain cancer 
  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Leukemia
  • Other Oncology applications
• Autoimmune disease 
  • Arthritis
    • Rheumatoid arthritis
    • Psoriatic arthritis
    • Juvenile arthritis
    • Ankylosing spondylitis
    • Other arthritis
  • Inflammatory bowel disease (IBD) 
    • Ulcerative colitis
    • Crohn's disease
    • Other IBD
  • Psoriasis
  • Other autoimmune diseases
• Ophthalmology
• Growth hormone deficiency 
• Diabetes
• Other applications

Market, By Manufacturing Type

• Contract research and manufacturing services

• In-house

Market, By Technology

• Recombinant DNA technology

• Mammalian cell culture systems
• Other technologies

Market, By Distribution Channel

• Hospital pharmacies 

• Specialty pharmacies
• Other distribution channels